Asset Details
Do you wish to reserve the book?
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
Do you wish to request the book?
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
2017
Overview
Immune checkpoint inhibitors and adoptive cell transfer (ACT) of autologous tumor-infiltrating T cells have shown durable responses in patients with melanoma. To study ACT and immunotherapies in a humanized model, we have developed PDXv2.0 — a melanoma PDX model where tumor cells and tumor-infiltrating T cells from the same patient are transplanted sequentially in non-obese diabetic/severe combined immune-deficient/common gamma chain (NOG/NSG) knockout mouse. Key to T-cell survival/effect in this model is the continuous presence of interleukin-2 (IL-2). Tumors that grow in PDXv2.0 are eradicated if the autologous tumor cells and T cells come from a patient that exhibited an objective response to ACT in the clinic. However, T cells from patients that are non-responders to ACT cannot kill tumor cells in PDXv2.0. Taken together, PDXv2.0 provides the potential framework to further model genetically diverse human cancers for assessing the efficacy of immunotherapies as well as combination therapies.
Combining different types of immune therapies might benefit certain patients. Here, the authors develop an autologous immune-humanized melanoma mouse model that allows the preclinical assessment of cancer cell–T cell interactions from each individual patient and the benefits of immunotherapies combinations.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Animals
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Humanities and Social Sciences
/ Humans
/ Immune checkpoint inhibitors
/ Interleukin Receptor Common gamma Subunit - genetics
/ Kirurgi
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Lymphocytes, Tumor-Infiltrating - pathology
/ Lymphocytes, Tumor-Infiltrating - transplantation
/ Melanoma
/ Patients
/ Science
/ Surgery
/ T-Lymphocytes - transplantation
/ Tumors
